DelveInsight’s, “Brain Metastases Pipeline Insights 2026” report provides comprehensive insights about 40+ Brain Metastases companies and 45+ pipeline drugs in Brain Metastases pipeline landscape. It covers the Brain Metastases pipeline drug profiles, including clinical and nonclinical stage products. Brain Metastases pipeline report also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore clinical-stage developments and strategic collaborations transforming the industry! @ https://www.delveinsight.com/sample-request/brain-metastases-pipeline-insight

Key Takeaways from the Brain Metastases Pipeline Report

• On June 05, 2026- UNICANCER conducted a phase 2 study evaluates the addition of stereotactic radiosurgery (SRS) to the combination of binimetinib + encorafenib + pembrolizumab in the treatment of BRAFⱽ⁶⁰⁰ mutation-positive melanoma with brain metastases (MBM).
• On June 04, 2026- Stemline Therapeutics Inc. announced a Phase 1b-2 study that includes a phase 1b evaluation of elacestrant in combination with abemaciclib in women and men with brain metastases from estrogen receptor (ER)-positive, human epidermal growth factor receptor-2 (HER-2) negative breast cancer. Phase 1b was designed to select the recommended phase 2 dose (RP2D) and is followed by an ongoing phase 2 evaluation of elacestrant in combination with abemaciclib in participants with active brain metastases from ER-positive, HER-2 negative breast cancer.
• On June 04, 2026- Memorial Sloan Kettering Cancer Center initiated a study is to see if Cs-131 brachytherapy is effective in people with recurrent brain cancer who are scheduled to have brain surgery for removal of their tumor(s). The researchers would like to see whether Cs-131 prevents brain tumors from growing back after surgery.The researchers will compare Cs-131 brachytherapy (which occurs during brain surgery) with the usual approach of brain surgery without brachytherapy. The researchers will compare both the effectiveness and safety of the two approaches.
• DelveInsight’s Brain Metastases pipeline report depicts a robust space with 40+ active players working to develop 45+ pipeline therapies for Brain Metastases treatment.
• The leading Brain Metastases Companies such as HUYA Bioscience International, LLC, Angiochem, Cantex Pharmaceuticals, Inc., Bristol-Myers Squibb, ImmunoChem Therapeutics, LLC, Kazia Therapeutics, Alpha Biopharma Ltd, Betta Pharmaceuticals Co., Ltd., TYK Medicines, Inc., BioMimetix JV, LLC, Amgen, Jubilant Therapeutics, Quadriga Biosciences, Inc., Pfizer, Medolution Ltd., Puma Biotechnology, Inc., Seagen Inc., Jiangsu Hansoh Pharmaceutical Co., Ltd., ABM Therapeutics Corporation and others.
• Promising Brain Metastases Pipeline Therapies such as GLIADEL, 18F fluciclovine, Pembrolizumab, IPILIMUMAB, Cabozantinib, Trastuzumab, capecitabine, lapatinib, Lenvatinib and others.

Learn how leading Brain Metastases Companies are positioning themselves for success in the evolving pharmaceutical market @ Brain Metastases Clinical Trials Assessment

The Brain Metastases Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Brain Metastases Pipeline Report also highlights the unmet needs with respect to the development of Brain Metastases.

Brain Metastases Overview

Brain metastases are a common complication of cancer and the most common type of brain tumor. Anywhere from 10% to 26% of patients who die from their cancer will develop brain metastases. While few cancers that metastasize to the brain can be cured using conventional therapies, long-term survival and palliation are possible with minimal adverse effects to patients. Increasingly, neuro-cognition and quality of life are being recognized as important endpoints for patients as survival continues to increase.

Brain Metastases Emerging Drugs Profile

• ANG1005: Angiochem

ANG1005 is a novel targeted taxane derivative that is the first oncology product to leverage Angiochem’s technology platform to cross the blood-brain barrier (BBB) and enter cancer cells. ANG1005 is an Angiopep-2 paclitaxel conjugate that gains entry into the brain by targeting the LRP-1, which is one of the most highly-expressed receptors on the surface of the BBB. Once inside the brain, ANG1005 enters tumor cells using the same receptor-mediated pathway through LRP-1, which is upregulated in various cancer cells including malignant glioma and metastatic cancers in the brain.

• Azeliragon: Cantex Pharmaceuticals, Inc.

Azeliragon, is an oral, small molecule, administered once-daily, that inhibits RAGE interactions with its natural ligands, including HMGB1 and S100 proteins, in the tumor microenvironment. Activation of RAGE by these ligands stimulates cancer and its progression and metastasis and resistance to cancer treatment.

• AZD3759: Alpha Biopharma Ltd.

Zorifertinib (AZD3759) is a type of reversible new generation EGFR TKI, which has a strong ability to penetrate the bloodstream, cerebrospinal fluid, and can reach blood volume in the tissue. It is currently investigated for brain metastases and completed Phase II/III trial in July 2022.

From early-stage research to late-phase Brain Metastases Clinical Trials, our analysis covers companies @ Brain Metastases Treatment Drugs

The Brain Metastases Pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Brain Metastases with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Brain Metastases Treatment.
• Brain Metastases Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Brain Metastases Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Brain Metastases market.

Brain Metastases Companies

HUYA Bioscience International, LLC, Angiochem, Cantex Pharmaceuticals, Inc., Bristol-Myers Squibb, ImmunoChem Therapeutics, LLC, Kazia Therapeutics, Alpha Biopharma Ltd, Betta Pharmaceuticals Co., Ltd., TYK Medicines, Inc., BioMimetix JV, LLC, Amgen, Jubilant Therapeutics, Quadriga Biosciences, Inc., Pfizer, Medolution Ltd., Puma Biotechnology, Inc., Seagen Inc., Jiangsu Hansoh Pharmaceutical Co., Ltd., ABM Therapeutics Corporation and others.

Brain metastases pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Brain Metastases Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Download our report for a deep dive into the next generation of therapeutics! @ Brain Metastases Market Drivers and Barriers, and Future Perspectives

Scope of the Brain Metastases Pipeline Report

• Coverage- Global
• Brain Metastases Companies- HUYA Bioscience International, LLC, Angiochem, Cantex Pharmaceuticals, Inc., Bristol-Myers Squibb, ImmunoChem Therapeutics, LLC, Kazia Therapeutics, Alpha Biopharma Ltd, Betta Pharmaceuticals Co., Ltd., TYK Medicines, Inc., BioMimetix JV, LLC, Amgen, Jubilant Therapeutics, Quadriga Biosciences, Inc., Pfizer, Medolution Ltd., Puma Biotechnology, Inc., Seagen Inc., Jiangsu Hansoh Pharmaceutical Co., Ltd., ABM Therapeutics Corporation and others.
• Brain Metastases Pipeline Therapies- GLIADEL, 18F fluciclovine, Pembrolizumab, IPILIMUMAB, Cabozantinib, Trastuzumab, capecitabine, lapatinib, Lenvatinib and others.
• Brain Metastases Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Brain Metastases Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Find answers in our latest Brain Metastases Pipeline Insights report, featuring in-depth coverage of Clinical Trials, regulatory trends, and upcoming breakthroughs @ Brain Metastases Emerging Drugs and Companies

Table of Contents

1. Introduction
2. Executive Summary
3. Brain metastases: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Brain metastases– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. ANG1005: Angiochem
9. Mid Stage Products (Phase II)
10. Paxalisib: Kazia Therapeutics
11. Early Stage Products (Phase I)
12. MW151: ImmunoChem Therapeutics, LLC
13. Preclinical and Discovery Stage Products
14. JBI-2174: Jubilant Therapeutics
15. Inactive Products
16. Brain metastases Key Companies
17. Brain metastases Key Products
18. Brain metastases- Unmet Needs
19. Brain metastases- Market Drivers and Barriers
20. Brain metastases- Future Perspectives and Conclusion
21. Brain metastases Analyst Views
22. Brain metastases Key Companies
23. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/brain-metastases-pipeline-insight